文献速递心境障碍老年精神会诊联络精神医学

药物与非药物干预对心境障碍患者躯体健康结局的影响:随机对照试验证据的伞状综述

The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials.
PubMed 文献 · Mol Psychiatry · 2022-09-22

结果显示心理治疗、运动和SSRIs对某些躯体健康结局有益,部分药物代谢中性,但多种药物干预与体重增加、代谢恶化等负面效应相关。

要点

  • 心理治疗和运动可改善某些躯体健康结局,如生活质量、心肺适能和血糖。
  • 多种抗精神病药(奥氮平、喹硫平、阿立哌唑等)与体重增加和代谢指标恶化相关。
  • 老年抑郁患者中氟西汀的心血管不良效应大于舍曲林/艾司西酞普兰。

核心结论

  • 心理治疗、运动和SSRIs可改善心境障碍患者的某些躯体健康结局,部分药物代谢中性,但多种药物干预与负面躯体健康效应相关。

主要发现

  • 青少年抑郁中,抗抑郁药/抗精神病药较安慰剂停药率更高;双相抑郁中奥氮平+氟西汀使总胆固醇、甘油三酯和体重增加恶化(大效应量)。
  • 成人双相障碍中,奥氮平使HbA1c、总胆固醇和体重增加恶化(中/大效应量);阿塞那平升高空腹血糖(小效应量);喹硫平、卡利拉嗪、利培酮诱导体重增加(小/中效应量);鲁拉西酮代谢中性。
  • 抑郁中,心理干预改善躯体健康相关生活质量(小效应量)及空腹血糖/HbA1c(中/大效应量);SSRIs改善空腹血糖/HbA1c、冠心病再入院和疼痛(小效应量);喹硫平/阿立哌唑/奥氮平诱导体重增加(小至大效应量);运动改善心肺适能(中效应量)。
  • 老年中,氟西汀较舍曲林/艾司西酞普兰产生更多不良心血管效应(大效应量);抗抑郁药对运动耐受性和躯体健康相关生活质量为中性。
  • 混合年龄组中,双相障碍阿立哌唑代谢中性;抑郁中SSRIs较安慰剂和SNRIs降低血压(小效应量);依匹哌唑增效导致体重增加且耐受性更差(小效应量);运动改善躯体健康相关生活质量(中效应量)。

临床怎么用

  • 优先选择对躯体健康有益或中性的有效治疗,如心理治疗、运动和SSRIs。
  • 对使用奥氮平、喹硫平、阿立哌唑等药物的患者应监测体重和代谢指标。
  • 老年抑郁患者选择抗抑郁药时需考虑心血管安全性差异。

局限性

  • 证据存在局限性,应考虑其他疾病领域的证据,并整合最新的单项随机对照试验和观察性证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: People with mood disorders have increased risk of comorbid medical diseases versus the general population. It is paramount to identify interventions to improve physical health in this population. METHODS: Umbrella review of meta-analyses of randomised controlled trials (RCTs) on pharmacological/non-pharmacological interventions for physical health outcomes/intolerability-related discontinuation in mood disorders (any age). RESULTS: Ninety-seven meta-analyses were included. Among youths, against placebo, in depression, antidepressants/antipsychotics had higher discontinuation rates; in bipolar depression, olanzapine+fluoxetine worsened total cholesterol (TC)/triglycerides/weight gain (WG) (large ES). In adults with bipolar disorder, olanzapine worsened HbA1c/TC/WG (moderate/large ES); asenapine increased fasting glucose (small ES); quetiapine/cariprazine/risperidone induced WG (small/moderate ES). In bipolar depression, lurasidone was metabolically neutral. In depression, psychological interventions improved physical health-related quality of life (PHQoL) (small ES), fasting glucose/HbA1c (medium/large ES); SSRIs improved fasting glucose/HbA1c, readmission for coronary disease, pain (small ES); quetiapine/aripiprazole/olanzapine induced WG (small to large ES). Exercise improved cardiorespiratory fitness (moderate ES). In the elderly, fluoxetine yielded more detrimental cardiovascular effects than sertraline/escitalopram (large ES); antidepressants were neutral on exercise tolerance and PHQoL. In mixed age groups, in bipolar disorder aripiprazole was metabolically neutral; in depression, SSRIs lowered blood pressure versus placebo and serotonin-noradrenaline reuptake inhibitors (small ES); brexpiprazole augmentation caused WG and was less tolerated (small ES); exercise improved PHQoL (moderate ES). CONCLUSIONS: Some interventions (psychological therapies, exercise and SSRIs) improve certain physical health outcomes in mood disorders, few are neutral, but various pharmacological interventions are associated with negative effects. Evidence from this umbrella review has limitations, should consider evidence from other disorders and should be integrated with recent evidence from individual RCTs, and observational evidence. Effective treatments with either beneficial or physically neutral profiles should be prioritized.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Croatto G, Vancampfort D, Miola A, et al. The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials. Mol Psychiatry. 2022. PMID: 36138129. doi:10.1038/s41380-022-01770-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。